Root Financial Partners LLC Acquires 5,115 Shares of AbbVie Inc. $ABBV

Root Financial Partners LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 71.0% during the third quarter, Holdings Channel.com reports. The fund owned 12,318 shares of the company’s stock after acquiring an additional 5,115 shares during the period. Root Financial Partners LLC’s holdings in AbbVie were worth $3,222,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ABBV. Carter Financial Group INC. raised its holdings in shares of AbbVie by 6.1% in the third quarter. Carter Financial Group INC. now owns 1,694 shares of the company’s stock worth $443,000 after acquiring an additional 98 shares during the last quarter. Boothe Investment Group Inc. lifted its position in shares of AbbVie by 3.7% in the third quarter. Boothe Investment Group Inc. now owns 32,895 shares of the company’s stock valued at $8,605,000 after acquiring an additional 1,187 shares in the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH boosted its stake in shares of AbbVie by 3.5% during the third quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 7,613 shares of the company’s stock valued at $1,991,000 after acquiring an additional 258 shares during the last quarter. JSF Financial LLC acquired a new stake in shares of AbbVie during the third quarter valued at $210,000. Finally, E. Ohman J or Asset Management AB boosted its stake in shares of AbbVie by 2.1% during the third quarter. E. Ohman J or Asset Management AB now owns 63,662 shares of the company’s stock valued at $16,653,000 after acquiring an additional 1,300 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Up 0.2%

ABBV opened at $285.66 on Friday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $291.40. The company has a 50 day moving average of $266.33 and a two-hundred day moving average of $241.77. The company has a market cap of $504.70 billion, a P/E ratio of 80.69, a P/E/G ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the business earned $2.97 earnings per share. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts anticipate that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is 195.48%.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

ABBV has been the subject of several analyst reports. Scotiabank boosted their target price on shares of AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Citigroup upped their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Weiss Ratings raised shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Argus lifted their price target on shares of AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Finally, BNP Paribas Exane boosted their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $279.86.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.